Navigation Links
Fighting disease deep inside the brain
Date:2/17/2013

Some 90,000 patients per year are treated for Parkinson's disease, a number that is expected to rise by 25 percent annually. Deep Brain Stimulation (DBS), which consists of electrically stimulating the central or peripheral nervous system, is currently standard practice for treating Parkinson's, but it can involve long, expensive surgeries with dramatic side effects. Miniature, ultra-flexible electrodes developed in Switzerland, however, could be the answer to more successful treatment for this and a host of other health issues.

Today, Professor Philippe Renaud of the cole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland reports on soft arrays of miniature electrodes developed in his Microsystems Laboratory that open new possibilities for more accurate and local DBS. At the 2013 Annual Meeting of the American Association for the Advancement of Science (AAAS) in Boston, in a symposium called "Engineering the Nervous System: Solutions to Restore Sight, Hearing, and Mobility," he announces the start of clinical trials and early, yet promising results in patients, and describes new developments in ultra-flexible electronics that can conform to the contours of the brainstemin the brain itselffor treating other disorders.

At AAAS, Renaud outlines the technology behind these novel electronic interfaces with the nervous system, the associated challenges, and their immense potential to enhance DBS and treat disease, even how ultra flexible electronics could lead to the auditory implants of the future and the restoration of hearing. "Although Deep Brain Stimulation has been used for the past two decades, we see little progress in its clinical outcomes," Renaud says. "Microelectrodes have the potential to open new therapeutic routes, with more efficiency and fewer side effects through a much better and finer control of electrical activation zones." The preliminary clinical trials related to this research are being done in conjunction with EPFL spin-off company Aleva Neurotherapeutics, the first company in the world to introduce microelectrodes in Deep Brain Stimulation leading to more precise directional stimulation.


'/>"/>

Contact: Hillary Sanctuary
hillary.sanctuary@epfl.ch
41-797-034-809
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Related biology technology :

1. Sabiya Donates Odor-Fighting Athletic Apparel to the Corps of Exploration Aboard E/V Nautilus
2. Fighting bacteria with mucus
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. The Foremost Expert on Morgellons Disease Highlights the Gravity of This Illness
5. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
6. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
7. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
8. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
9. A mouse model brings new perspectives on Lafora disease
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... Diego, CA (PRWEB) , ... May 20, 2017 ... ... support tool that helps avoid the lengthy trial and error process by finding ... patients. It can also strengthen the doctor-patient relationship through a personalized approach ...
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... ... procedure on April 28, 2017 at the Prince Of Wales Private Hospital. The ... disc at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl ... CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal ... at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, is ... UDIs and Traceability for Medical Devices conference in Brussels, Belgium. , Crowley played ...
Breaking Biology Technology:
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
Breaking Biology News(10 mins):